Cite
Sliz E, Kettunen J, Holmes MV, et al. Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment. Circulation. 2018;138(22):2499–2512doi: 10.1161/CIRCULATIONAHA.118.034942.
Sliz, E., Kettunen, J., Holmes, M. V., Williams, C. O., Boachie, C., Wang, Q., Männikkö, M., Sebert, S., Walters, R., Lin, K., Millwood, L. Y., Clarke, R., Li, L., Rankin, N., Welsh, P., Delles, C., Jukema, J. W., Trompet, S., Ford, I., Perola, M., Salomaa, V., Järvelin, M. R., Chen, Z., Lawlor, D. A., Ala-Korpela, M., Danesh, J., Smith, G. D., Sattar, N., Butterworth, A., & Würtz, P. (2018). Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment. Circulation, 138(22), 2499–2512. https://doi.org/10.1161/CIRCULATIONAHA.118.034942
Sliz, Eeva, et al. "Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment." Circulation vol. 138,22 (2018): 2499–2512. doi: https://doi.org/10.1161/CIRCULATIONAHA.118.034942
Sliz E, Kettunen J, Holmes MV, Williams CO, Boachie C, Wang Q, Männikkö M, Sebert S, Walters R, Lin K, Millwood LY, Clarke R, Li L, Rankin N, Welsh P, Delles C, Jukema JW, Trompet S, Ford I, Perola M, Salomaa V, Järvelin MR, Chen Z, Lawlor DA, Ala-Korpela M, Danesh J, Smith GD, Sattar N, Butterworth A, Würtz P. Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment. Circulation. 2018 Nov 27;138(22):2499–2512. doi: 10.1161/CIRCULATIONAHA.118.034942. PMID: 30525347; PMCID: PMC6254781.
Copy
Download .nbib